 Phase two, 200 cases of LABC primary resistant of antharcycline and taxans. Patients were randomized to Arm ddEC-T-H and Arm PERS regimens according to PERS,eg NVBDDP,capacitabine,gemcitabine and so on pCR rate and DFS is observed. 